Cutaneous Squamous Cell Carcinoma
Dec 17, 2024
FDA Approves Neurocrine’s CRENESSITY for Congenital Adrenal Hyperplasia; Checkpoint’s UNLOXCYT Approved; MAIA’s THIO Gets Rare Pediatric Disease Designation; JEMPERLI Receives Breakthrough Therapy for Rectal Cancer; Galderma’s NEMLUVIO Approved for Atopic Dermatitis.
Neurocrine Announces FDA Approval of CRENESSITY for Congenital Adrenal Hyperplasia Neurocrine Biosciences, Inc. announced that the FDA has approved CRENESSITY™ (crinecerfont) as an adjunctive treatment to glucocorticoid replacement for controlling androgens in adult and pediatric patients aged four years and old...
Read More...
Sep 03, 2024
Bayer Phase III NSCLC Trial; D&D Pharmatech Gets FDA Nod for GLP-1R Agonist in Multiple Scletosis; Merck Halts Two KEYTRUDA Trials; Novartis Expands LEQVIO After Phase III Success; Alnylam Reports Strong Phase III Data for Vutrisiran
Bayer Starts Phase III Trial In Non-Small Cell Lung Cancer (NSCLC) Bayer has officially enrolled the first patient in the global Phase III SOHO-02 trial, which will evaluate the efficacy and safety of BAY 2927088 as a first-line treatment for advanced non-small cell lung cancer (NSCLC) with activating HER2 mutat...
Read More...
Jul 04, 2019
EU approval for Libtayo and Dovato; Boehringer expands NASH pipeline
EU approves the use of Libtayo for cutaneous squamous cell carcinoma The National Institute for Health and Care Excellence (NICE), in a move to make cancer drugs available to common man, has issued guidelines regarding the funding of Libtayo (cemiplima). Libtayo, co-developed by Sanofi and Regeneron, was granted...
Read More...
May 12, 2017
Cutaneous Melanoma Market Overview & Pipeline Analysis
Non-melanoma skin cancer is a group of cancers of the skin and is broadly classified into Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC). It has the greatest prevalence in the United States, which can be seen through statistics which show that basal cell carcinoma accounts for 80% while Squamous cell c...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
